Note: Descriptions are shown in the official language in which they were submitted.
WO 2011/140092 PCT/US2011/035007
BIFUNCTIONAL MOLECULES FOR INACTIVATING HIV AND BLOCKING HIV
ENTRY
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit under 35 U.S.C. 119(e) to
provisional
patent application 61/330,787 filed May 3, 2011, the entire contents of which
is
incorporated by reference herein.
FIELD OF THE INVENTION
[0002] The field of this disclosure related to peptide compounds for treating
human immunodeficiency virus-related diseases.
BACKGROUND OF THE INVENTION
[0003] By the end of 2007, about 33.2 million people in the world are living
with
human immunodeficiency virus (HIV) infection and more than 25 million people
have
died of Acquired Immunodeficiency Syndrome (AIDS). Therefore, it is urgently
needed to discover and develop new therapeutic strategies against HIV
infection. So
far, 28 anti-HIV drugs have been approved by the Food and Drug Administration
of
the United States to treat people infected with HIV, including 15 reverse
transcriptase inhibitors (RTIs), 10 protease inhibitors (Pis), one integrase
inhibitor (II),
and two entry inhibitors (Els). All the RTIs, Pis, and II inhibit HIV
replication after the
virus enters the host cells. The two Els can block HIV entry into the host
cell, but
they cannot inactivate virus before HIV attaches to the target cell.
[0004] One of the Els is a synthetic peptide designed based on the sequence of
the HIV envelope protein (Env) transmembrane subunit gp4l C-terminal heptad
repeat (CHR) region, named T20 (enfuvirtide, FUZEON ), which inhibits HIV
fusion
with the host cell by targeting gp4l. T20 inhibits HIV entry by targeting HIV
envelope
protein (Env) gp4l, which consists of fusion peptide (FP), and N- and C-
terminal
heptad repeats (NHR and CHR) (FIG. 1). In the native state, gp4l is
inaccessible
since it is buried underneath HIV Env gp120. At the beginning of HIV infection
process, gp120 binds to CD4 on the target cell, causing gp4l to change
conformation: (1) FP inserts into the target cell membrane; (2) NHR associates
to
form an NHR-trimer, and (3) CHR interacts with NHR-trimer to form a hairpin-
like six-
1
WO 2011/140092 PCT/US2011/035007
helix bundle (6-HB) which brings the viral and cellular membranes into close
proximity which is necessary for fusion. T20 and C34, another CHR peptide (CP)
can
bind to the viral gp4l NHR-trimer and block 6-HB formation, resulting in
inhibition of
HIV fusion. However, T20 cannot inactivate HIV circulating in the blood before
the
virus attaches to the target cell because it can only interact with HIV after
the virus
comes into contact with CD4 on the target cell. Because of this problem, the
T20
peptide must be maintained in the blood of HIV/AIDS patients at a constant
high
concentration. Therefore, T20 has to be administrated by injection twice a day
at 90
mg/dose, resulting in painful injection-site reactions in most patients and
high cost to
the patients (>$20,000/year/patient). Consequently, T20 is exorbitantly
expensive for
use in developing countries. Therefore, improved drugs for treating HIV
infection and
AIDS are needed.
BRIEF DESCRIPTION OF THE DRAWINGS
[0005] FIG. 1 depicts a schematic view of gp4l functional domains. The residue
number corresponds to its position in HIV-1 HXB2 gp160. FP, fusion peptide;
TR,
tryptophan-rich region; TM, transmembrane domain; CP, cytoplasmic domain.
[0006] FIG. 2 depicts interactions between the N-terminal heptad repeat (NHR)
and C-terminal heptad repeat (CHR) of gp4l and between N- and C-peptides. The
dashed lines between NHR and CHR indicate the interaction between the residues
located at the e and g positions in the NHR and the a and d positions in the
CHR.
[0007] FIG. 3 depicts a model of gp41-mediated HIV fusion and mechanisms of
action of NHR-binding protein (NBP) and a bifunctional molecule, 2D-NBP. The
NBP (e.g., C46, C34, T1144, and T20) binds to gp4l NHR, resulting in
inhibition of
HIV with the target cell (iii). 2D-NBP binds to gpl20, via its 2D domain, and
interacts,
via NBP domain, with gp4l NHR, leading to irreversible inactivation of HIV
(i). Like
NBP, 2D-NBP can also inhibit virus fusion with the target cell (ii).
[0008] FIG. 4 depicts a model of gp41-mediated HIV fusion and mechanisms of
action of CHR-binding protein (CBP) and a bifunctional molecule, 2D-CBP. The
CBP (e.g., N46 and N36) binds to gp4l CHR, resulting in inhibition of HIV with
the
target cell (iii). 2D-CBP binds to gp120, via its 2D domain and interacts, via
CBP
2
WO 2011/140092 PCT/US2011/035007
domain, with gp4l CHR, leading to irreversible inactivation of HIV (i). Like
CBP, 2D-
CBP can also inhibit virus fusion with the target cell (ii).
[0009] FIG. 5 depicts the model of gp4l-mediated HIV fusion and mechanisms
of action of FP-binding protein (FBP) and a bifunctional molecule, 2D-FBP. The
FBP
(e.g., VIRIP-1) binds to gp4l FP, resulting in inhibition of HIV with the
target cell (iii).
2D-FBP binds to gp120, via its 2D domain, and interacts via FBP domain, with
gp4l
NHR, leading to irreversible inactivation of HIV (i). Like FBP, 2D-FBP can
also inhibit
virus fusion with the target cell (ii).
[0010] FIG. 6 depicts SDS-PAGE (FIG. 6A) and Western blot (FIG. 6B and 6C)
analysis of the purified 2D and 2D-NBP8.
[0011] FIG. 7 depicts the biological character of the 2D (D1 D2 domain of
sCD4).
Polyclonal antibodies (T4-4), conformation-dependent Sim.4 monoclonal antibody
against CD4, and polyclonal antibodies against NBP8 were used to detect bound
recombinant 2D molecule.
[0012] FIG. 8 depicts the biological character of the 2D-NBP8. Polyclonal
antibodies (T4-4), conformation-dependent Sim.4 monoclonal antibody against
CD4
and polyclonal antibodies against NBP8 were used to detect bound recombinant
2D-
NBP8 molecule.
[0013] FIG. 9 depicts the binding activity of 2D and 2D-NBP8 to recombinant
gp120.
[0014] FIG. 10 depicts the binding activity of 2D and 2D-NBP8 to 5-helix.
[0015] FIG. 11 depicts the functional activity of the 2D and 2D-NBP8. 2D
(FIGs.
11 B and 11 F) and 2D-NBP8 (FIGs. 11 C and 11 G) both have the binding ability
to
wild type gpl20/gp4l on the surface CHO-WT (FIGs. 11E-H) as detected by flow
cytometric analysis. CHO-EE (FIGs. 11A-D) expressing no gpl20/gp4l were
included as control. FIGs. 11A and 11 E depict the sCD4 control and FIGs. 11 D
and
11 H depict the NBP8 control.
[0016] FIG. 12 depicts the binding affinity of 2D and 2D-NBP8 by surface
plasmon resonance (SPR) analysis. FIG. 12A - Binding of 2D with gpl 20. FIG.
12B
- Binding of 2D-NBP8 with gpl 20. FIG. 12C - Binding of NBP8 with gpl 20.
3
WO 2011/140092 PCT/US2011/035007
[0017] FIG. 13 depicts the inhibitory effect of 2D-NBP8 on 6-HB formation in
the
ELISA assay.
[0018] FIG. 14 depicts the inhibitory effect of 2D-NBP8 on 6-HB formation in
the
Fluorescence Native-PAGE assay (FN-PAGE). FIGs. 14A and 14C - FN-PAGE
analysis. FIGs. 14B and 14D - Coomassie blue staining of FN-PAGE gel.
[0019] FIG. 15 depicts the inhibition by 2D and 2D-NBP8 of infection by a
laboratory-adapted HIV-1 IIIB strain (subtype B, X4) in MT-2 cells as
determined by
p24 assay.
[0020] FIG. 16 depicts the inhibition by 2D and 2D-NBP8 of infection by a HIV-
1
Bal strain (subtype B, R5) in M7 cells as determined by luciferase assay.
[0021] FIG. 17 depicts the virus inactivation activity of 2D, 2D-NBP8, NBP8
and
T20 by a laboratory-adapted HIV-1 IIIB strain (subtype B, X4) in MT-2 cells as
determined by p24 assay.
[0022] FIG. 18 depicts the virus inactivation activity of 2D, 2D-NBP8, NBP8
and
T20 by a HIV-1 Bal strain (subtype B, R5) in M7 cells as determined by
luciferase
assay.
[0023] FIG. 19 depicts the destabilization by 2D-NBP8 of 2D-activated envelope
glycoprotein intermediate through interacting with exposed N-HR domain at 4 C
(FIG. 19A) and 25 C (FIG. 19B).
[0024] FIG. 20 depicts the inhibition of infectivity of cell-bound virus
activated by
2D.
SUMMARY OF THE INVENTION
[0025] Bifunctional molecules (designated 2D-CP) are disclosed herein which
contain: (i) a soluble CD4 (sCD4) or D1 D2 domain of sCD4 (2D), which can bind
to
gp120 to trigger a conformational change in gp4l, leading to exposure of the
NHR,
CHR and FP; (ii) a NHR-, CHR- or FP-binding peptide (CP) which can interact
with
the gp4l NHR, CHR or FP, respectively; (iii) a flexible linker consisting of
10 to 40
amino acids ((GGGGS)n, wherein n=2-8) to link the 2D and CP so that these two
functional domains can move freely to bind corresponding target proteins on
HIV or
HIV-infected cells.
4
WO 2011/140092 PCT/US2011/035007
[0026] These bifunctional molecules inactivate HIV even before the virus
attacks
the target cell and inhibit HIV entry into the target cell. These molecules
can be
further developed as novel anti-HIV therapeutics for treatment of patents
infected by
HIV, including non-B and multi-drug resistant strains, through a mechanism of
action
that is different from current anti-HIV drugs.
[0027] In one embodiment disclosed herein, a pharmaceutical composition is
provided comprising a polypeptide comprising a first domain comprising a
soluble
CD4 or a portion of soluble CD4; a second domain comprising a human
immunodeficiency virus (HIV) gp4l functional domain-binding sequence selected
from the group consisting of N-terminal heptad repeat (NHR)-binding peptides,
C-
terminal heptad repeat (CHR)-binding peptides and fusion peptide (FP)-binding
peptides; and a flexible linker linking the amino acid sequences of the first
domain
and the second domain, wherein the linker comprises the amino acid sequence
(GGGGS)n, wherein n is an integer between 2 and 8.
[0028] In another embodiment, the portion of soluble CD4 comprises the D1 D2
domain of sCD4. In another embodiment, the NHR-binding peptide is selected
from
the group consisting of C46, C38, C36, C34, C28, C51, sifuvirtide, T1144,
CP621-
652, CP32M, T1249, PBD-4HR, CBD1, and T20; the CHR-binding peptide is
selected from the group consisting of N46, N36, N34, N51, DP107, N17, and N28;
and the FP-binding peptide is selected from the group consisting of VIRIP164,
VIRIP165, VIRIP353, and VIRIP576.
[0029] In yet another embodiment, the polypeptide comprises an amino acid
sequence selected from the group consisting of SEQ ID NOs:37-62.
[0030] In yet another embodiment, the composition further includes at least
one
pharmaceutically acceptable excipient.
[0031] In one embodiment, disclosed herein, a method of treating a viral
infection
is provided comprising administering an effective dose of the disclosed
pharmaceutical composition to an individual exposed to an HIV infection;
inactivating
HIV, and blocking entry of HIV into a target cell, thereby treating the viral
infection.
In another embodiment, the pharmaceutical composition comprises a polypeptide
WO 2011/140092 PCT/US2011/035007
comprising an amino acid sequence selected from the group consisting of SEQ ID
NOs:37-62.
[0032] In one embodiment disclosed herein, a method of preventing a viral
infection is provided comprising administering an effective dose of the
disclosed
pharmaceutical composition to an individual who has been exposed to or will be
exposed to HIV; inactivating HIV, and blocking entry of HIV into a target
cell, thereby
preventing the viral infection. In another embodiment, the pharmaceutical
composition is administered topically to prevent sexual transmission of HIV.
In yet
another embodiment, the pharmaceutical composition comprises a polypeptide
comprising an amino acid sequence selected from the group consisting of SEQ ID
NOs:37-62.
DETAILED DESCRIPTION OF THE INVENTION
[0033] Bifunctional molecules (designated 2D-CP) are disclosed herein which
contain: (i) a first domain comprising a soluble CD4 (sCD4) or D1 D2 domain of
sCD4
(2D), which can bind to gp120 to trigger a conformational change in gp4l,
leading to
exposure of the gp4l N-terminal heptad repeat (NHR), C-terminal heptad repeat
(CHR) or fusion peptide (FP); (ii) a second domain comprising a NHR-, CHR- or
FP-
binding peptide (CP) which can interact with the gp4l a NHR-, CHR- or FP,
respectively; (iii) and a flexible linker consisting of 10 to 40 amino acids
((GGGGS)n,
wherein n=2-8) to link the first domain (2D) and second domain (CP) so that
these
two functional domains can move freely to bind corresponding target proteins
on
human immunodeficiency virus (HIV) or HIV-infected cells. The designed
molecules
are expressed in E. coli or 293T cells, purified by chromatography and tested
for
their inhibitory activity on HIV-mediated cell-cell fusion and HIV
replication, as well as
for their ability to inactivate cell-free and cell-associated HIV.
[0034] Disclosed herein are a series of bifunctional molecules, designated D1
D2-
NHR-binding peptide (2D-NBP), D1 D2-CHR-binding peptide (2D-CBP), and D1 D2-
FP-binding peptide (2D-FBP), which inactivate HIV by binding to gp120 and gp4l
NHR, CHR or FP, via 2D (D1 D2 domain of soluble CD4) and NBP, CBP, or FBP,
respectively, and/or to inhibit HIV fusion and entry into the target cell by
interacting
with the gp4l pre-hairpin intermediate structure through its NHR, CHR or FP
6
WO 2011/140092 PCT/US2011/035007
domain. These hybrid molecules can function as a double guard in that 1) they
kill
HIV before the virus comes into contact with the target cells; and 2) they
block HIV
entry into the target cell after the virus attaches to the cell, in case the
virus has
escaped the first attack by the molecules.
[0035] The disclosed bifunctional molecules have great potential to be
developed
as novel anti-HIV therapeutics that can be used in both developing and
developed
countries. Compared with the current anti-HIV drugs, 2D-CPs have unique
mechanism of action, namely inactivation of HIV. Because their mechanism of
action
is different from those of other anti-HIV drugs in clinical use, 2D-CPs are
expected to
be effective against HIV isolates with multiple drug resistance. The
combination of
2D-CPs with other anti-HIV drugs may have synergistic anti-HIV effects.
Compared
with the T20 peptide, 2D-CPs have higher in vivo efficacy, since they can both
inactivate HIV that circulates in the blood at any given time and can also
inhibit HIV
fusion and entry. In comparison, T20 can only inhibit HIV fusion during a
brief time
window (<20 minutes), i.e. during gp4l's conformational change from the native
to
intermediate state, which is triggered by gp120 binding to the CD4+ target
cell.
Therefore, lower dosages and less frequent injections of 2D-CPs than T20 may
be
required to eliminate HIV in blood or reduce the viral load. Consequently, 2D-
CPs
will be less costly to patients and cause them less suffering from injection-
site
reactions. Furthermore, 2D-CPs, as recombinant proteins, may have lower
production cost (since they can be expressed on a large scale) and a higher
stability
and half-life (because of its larger molecular size) than the synthetic
peptide T20,
and therefore are expected to be more affordable for developing countries.
[0036] Exemplary CPs include, but are not limited to, C46 (SEQ ID NO:6), C38
(SEQ ID NO:7), C36 (SEQ ID NO:8), C34 (SEQ ID NO:4), C28 (SEQ ID NO:9), C51
(SEQ ID NO:10), sifuvirtide (SEQ ID NO:11), T1144 (SEQ ID NO:12), C35-EK (SEQ
ID NO:63), CP621-652 (SEQ ID NO:13), CP32M (SEQ ID NO:14), T1249 (SEQ ID
NO:15), PBD-4HR (SEQ ID NO:16), CBD1 (SEQ ID NO:17), T20 (SEQ ID NO:5),
N46 (SEQ ID NO:18), N36 (SEQ ID NO:1), N34 (SEQ ID NO:19), N51 (SEQ ID
NO:20), DP107 (SEQ ID NO:21), N17 (SEQ ID NO:22), N28 (SEQ ID NO:2),
VIRIP164 (SEQ ID NO:23), VIRIP165 (SEQ ID NO:24), VIRIP353 (SEQ ID NO:25),
and VIRIP576 (SEQ ID NO:26).
7
WO 2011/140092 PCT/US2011/035007
[0037] Moreover, pharmaceutical compositions are disclosed herein which are
85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to
the amino acid sequences of SEQ ID NOs: 37-62. Identity or homology with
respect
to such sequences is defined herein as the percentage of amino acid residues
in the
candidate sequence that are identical with SEQ ID NOs: 37-62, after aligning
the
sequences and introducing gaps, if necessary, to achieve the maximum percent
homology, and not considering any conservative substitutions as part of the
sequence identity. Fusion proteins, or N-terminal, C-terminal or internal
extensions,
deletions, or insertions into the peptide sequence shall not be construed as
affecting
homology.
[0038] Thus, the proteins disclosed herein include molecules having the amino
acid sequence of SEQ ID NOs:37-62; amino acid sequence variants wherein one or
more amino acid residues has been inserted N- or C-terminal to, or within, the
disclosed coding sequence; and amino acid sequence variants of the disclosed
sequence, or their fragments as defined above, that have been substituted by
at
least one residue. Such fragments, also referred to as peptides or
polypeptides, may
contain antigenic regions, functional regions of the protein identified as
regions of the
amino acid sequence which correspond to known protein domains, as well as
regions of pronounced hydrophilicity. The regions are all easily identifiable
by using
commonly available protein sequence analysis software such as MacVector
(Oxford
Molecular).
[0039] As used herein, the designation of an amino acid residue in the instant
peptides as more than one amino acid (using the common one-letter amino acid
code) in parenthesis with a slash between the amino acids, means that any of
the
indicated amino acids, or mimetics thereof (unless specifically excluded),
could
occupy that residue. For example, (I/L/V)(T/S/A/V/C) means that the first
residue can
be any one of isoleucine, leucine, or valine, and the second residue can be
any one
of threonine, serine, alanine, valine, or cysteine, or mimetics.
[0040] The amino acid residues for the disclosed peptides include conservative
amino acid substitutions. For example, conservative amino acid changes may be
made which, although they alter the primary sequence of the protein or
peptide, do
8
WO 2011/140092 PCT/US2011/035007
not normally alter its function. Conservative amino acid substitutions
typically include
substitutions within the following groups: glycine and alanine; valine,
isoleucine and
leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and
threonine; lysine and arginine; and phenylalanine and tyrosine.
[0041] The present disclosure is also directed to pharmaceutical compositions
comprising the above-described bifunctional peptides that can inhibit HIV
entry into a
target cell, in a pharmaceutically acceptable carrier.
[0042] Dosages and desired drug concentrations of the disclosed
pharmaceutical compositions may vary depending on the particular use
envisioned.
The determination of the appropriate dosage or route of administration is well
within
the skill of an ordinary physician. Animal experiments provide reliable
guidance for
the determination of effective doses for human therapy. Interspecies scaling
of
effective doses can be performed following the principles laid down by
Mardenti, J.
and Chappell, W. "The use of interspecies scaling in toxicokinetics" In
Toxicokinetics
and New Drug Development, Yacobi et al, Eds., Pergamon Press, New York 1989,
pp. 42-96. The term "therapeutically effective" amount as used herein refers
to the
amount needed to perform the particular treatment for a disease such as, for
example, an infectious disease. "Treatment" refers to both therapeutic
treatment and
prophylactic or preventative measures, wherein the object is to prevent or
slow down
(lessen) the targeted pathologic condition or disease. Those in need of
treatment
include those already with the disease as well as those prone to have the
disease or
those in whom the disease is to be prevented. In one embodiment, the disease
is
present. In another embodiment, the life of a cell or an individual is
prolonged due to
the methods described herein.
[0043] 2D-CPs have the potential to be developed as novel anti-HIV
therapeutics
for treating patients infected by HIV, including non-B and multi-drug
resistant strains,
as prophylactic agents for pre- and post-exposure prophylaxis of HIV
infection, and
as microbicides for prevention of sexual transmission of HIV.
[0044] The above-described compounds can be formulated without undue
experimentation for administration to a mammal, including humans, as
appropriate
for the particular application. Additionally, proper dosages of the
compositions can
9
WO 2011/140092 PCT/US2011/035007
be determined without undue experimentation using standard dose-response
protocols.
[0045] Accordingly, the compositions designed for oral, nasal, lingual,
sublingual,
buccal and intrabuccal administration can be made without undue
experimentation
by means well known in the art, for example with an inert diluent or with an
pharmaceutically acceptable carrier. The compositions are enclosed in gelatin
capsules or compressed into tablets. For the purpose of oral therapeutic
administration, the pharmaceutical compositions may be incorporated with
excipients
and used in the form of tablets, troches, capsules, elixirs, suspensions,
syrups,
wafers, chewing gums and the like. A "pharmaceutically acceptable carrier"
means
any of the standard pharmaceutical carriers. Examples of suitable carriers are
well
known in the art and may include but are not limited to any of the standard
pharmaceutical carriers like phosphate buffered saline solutions, phosphate
buffered
saline containing Polysorb 80, water, emulsions such as oil/water emulsion,
and
various types of wetting agents. Other carriers may also include sterile
solutions,
tablets, coated tablets, and capsules. Typically such carriers contain
excipients like
starch, milk, sugar, certain types of clay, gelatin, stearic acid or salts
thereof,
magnesium or calcium stearate, talc, vegetable fats or oils, gums, glycols, or
other
known excipients. Such carriers may also include flavor and color additives or
other
ingredients. Compositions comprising such carriers are formulated by well
known
conventional methods.
[0046] Tablets, pills, capsules, troches and the like may also contain
binders,
excipients, disintegrating agent, lubricants, sweetening agents, and flavoring
agents.
Some examples of binders include microcrystalline cellulose, gum tragacanth or
gelatin. Examples of excipients include starch or lactose. Some examples of
disintegrating agents include alginic acid, cornstarch and the like. Examples
of
lubricants include magnesium stearate or potassium stearate. An example of a
glidant is colloidal silicon dioxide. Some examples of sweetening agents
include
sucrose, saccharin and the like. Examples of flavoring agents include
peppermint,
methyl salicylate, orange flavoring and the like. Materials used in preparing
these
various compositions should be pharmaceutically pure and nontoxic in the
amounts
used.
WO 2011/140092 PCT/US2011/035007
[0047] The compounds can easily be administered parenterally such as for
example, by intravenous, intramuscular, intrathecal or subcutaneous injection.
Parenteral administration can be accomplished by incorporating the compounds
into
a solution or suspension. Such solutions or suspensions may also include
sterile
diluents such as water for injection, saline solution, fixed oils,
polyethylene glycols,
glycerine, propylene glycol or other synthetic solvents. Parenteral
formulations may
also include antibacterial agents such as for example, benzyl alcohol or
methyl
parabens, antioxidants such as for example, ascorbic acid or sodium bisulfite
and
chelating agents such as EDTA. Buffers such as acetates, citrates or
phosphates
and agents for the adjustment of tonicity such as sodium chloride or dextrose
may
also be added. The parenteral preparation can be enclosed in ampules,
disposable
syringes or multiple dose vials made of glass or plastic.
[0048] Rectal administration includes administering the compound, in a
pharmaceutical composition, into the rectum or large intestine. This can be
accomplished using suppositories, enemas, gels, creams, tablets, and the like.
Suppository formulations can easily be made by methods known in the art.
Similarly,
vaginal administration forms comprising suppositories, gels, douches, creams,
tablet,
rings and the like can be formulated. The composition may be intended for
rectal or
vaginal administration, in the form, e.g., of a suppository which will melt in
the rectum
and release the drug. The composition for rectal or vaginal administration may
contain an oleaginous base as a suitable nonirritating excipient. Such bases
include,
without limitation, lanolin, cocoa butter and polyethylene glycol. Low-melting
waxes
are preferred for the preparation of a suppository, where mixtures of fatty
acid
glycerides and/or cocoa butter are suitable waxes. The waxes may be melted,
and
the cyclohexylamine compound is dispersed homogeneously therein by stirring.
The
molten homogeneous mixture is then poured into convenient sized molds, allowed
to
cool and thereby solidify.
[0049] The disclosed composition intended for topical administration may
suitably comprise a solution, emulsion, ointment, cream or gel base. The base,
for
example, may comprise one or more of the following: petrolatum, lanolin,
polyethylene glycols, bee wax, mineral oil, diluents such as water and
alcohol, and
11
WO 2011/140092 PCT/US2011/035007
emulsifiers and stabilizers. Thickening agents may be present in a
pharmaceutical
composition for topical administration.
[0050] Transdermal administration includes percutaneous absorption of the
composition through the skin. Transdermal formulations include patches,
iontophoresis devices, ointments, creams, gels, salves and the like.
[0051] The composition may include various materials which modify the physical
form of a solid or liquid dosage unit. For example, the composition may
include
materials that form a coating shell around the active ingredients. The
materials which
form the coating shell are typically inert, and may be selected from, for
example,
sugar, shellac, and other enteric coating agents. Alternatively, the active
ingredients
may be encased in a gelatin capsule or cachet
EXAMPLES
Example 1
Expression and purification of the bifunctional molecule 2D-NBP8
[0052] To create the expression plasmid p2D-NBP8-PDI, DNA fragments
encoding 2D, the 35-mer linker (GGGGS)7 (SEQ ID NO:34), and NBP8 (SEQ NO:12)
were linked together by three-step overlapping PCR. Firstly, the 2D (with 6-
his tag),
L35 and NBP8 DNA fragments were generated by overlapping PCR using the
corresponding primer pairs as depicted in Table 1. Secondly, the DNA fragments
coding for L35 and NBP8 were linked by overlapping PCR with the primers FL35
and
RNBP8. Thirdly, the two DNA fragments encoding 2D and L35-NBP8 were linked by
overlapping PCR with the DNA fragment 2D and the primers F2Dhis and RNBP8.
Finally, the amplified DNA fragment coding for NBP8-L35-T20 was digested by
BamHI and EcoRI and inserted into the expression vector pGEX-6p-1 to generate
the p2D-NBP8 plasmid. In order to prevent the formation of the inclusion
bodies in
E.coli, the protein disulfide isomerase (PDI) DNA sequence (aal8-508) with a
precision protease site (called ppase site) was inserted in the N terminus
into the
EcoR I and Xho I sites located at the C terminus of His-2D-NBP8 gene in the
plasmid p2D-NBP8 to extend the GST-his-2D-NBP8 reading frame and resulted in
the generation of chimeric GST-his-2D-NBP8-ppase-PDI. This plasmid was called
p2D-NBP8-PDI. These sequences were confirmed by DNA sequencing.
12
WO 2011/140092 PCT/US2011/035007
Table 1. Primers used for constructing the expression vector, pTLT-1
DNA fragment Primer Sequence (5' to 3')*
encoding
F2Dhis CGCGGATCCCATCACCATCACCATCATAAGAAAGTGGTGCT
2D G (SEQ ID NO:27)
CACTTCCTCCTCCTCCTATGCTGGAGGCCTTCTGGAA (SEQ
R2D ID NO:28)
GGAGGAGGAGGAAGTGGCGGCGGCGGCTCGGGTGGTGG
FL35 TGGTTCTGGAGGTGGCGGTAGCGGAGGTGGAGGTAGTGG
35-mer linker AGGC (SEQ ID NO:29)
GCTACCTCCGCCTCCCGAACCTCCGCCTCCACTACCTCCA
RL35 CCTCCGCTACCGCCACCTCCAGAACCACCACCACCCGAG
(SEQ ID NO:30)
GAGGCGGAGGTAGCACGACCTGGGAAGCATGGGACAGAG
FNBP8 CTATTGCTGAATACGCAGCTAGGATAGAAGCTTTACTCAGA
GCTTTA (SEQ ID NO:31)
NBP8 CGGAGATCTCTATAATTCCCTTAAGGCTGCTTCATTCTTTTC
RNBP8 TTGCTGTTCTTGTAAAGCTCTGAGTAAAGCTTCTATCC (SEQ
ID NO:32)
*The sequences underlined are restriction enzyme sites used for clone gene
into vector
pGEX-6p-1.
[0053] To express the 2D-NBP8 fusion protein, E. coli strain Rosetta 2 (DE3)
pLysS (Novagen) was transformed with p2D-NBP8-PDI, cultured at 37 C to
OD600=0.4, then induced at 16-22 C for 8-12 hr. The cells were harvested and
lysed
by sonication in presence of protease inhibitor mixture (Roche). After
centrifugation,
supernatant containing the GST-his-2D-NBP8-PDI fusion protein were collected.
The
protein was then purified with GIutathione-Sepharose 4B affinity columns and
cleaved with PreScissionTM Protease (GE Healthcare) to release the
bifunctional
proteins from the GST and PDI. The bifunctional proteins were then purified by
His-
bind Purification Kit (Novagen) and fast protein liquid chromatography (FPLC)
and
analyzed by SDS-PAGE.
[0054] The originally designed bifunctional protein consisted of a 185-mer of
2D
(KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRAD
SRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGQS
LTLTLESPPGSSPSVQCRSPRGKN IQGGKTLSVSQLELQDSGTWTCTVLQNQKKV
EFKIDIVVLAFQKASSI; SEQ ID NO:33), a 35-mer of linker [(GGGGS)7; SEQ ID
NO:34)] and a 38-mer of NBP8
13
WO 2011/140092 PCT/US2011/035007
(TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALREL; SEQ ID NO:12).
Sequencing the resultant vectors indicated that eleven extra amino acid
residues
(GPLGSHHHHHH; SEQ ID NO:35) at the N-terminus and had eight extra amino acid
residues (EFLEVLFQ; SEQ ID NO:36) at the C-termini. The purified bifunctional
protein demonstrated a molecular weight of about 30 kD by SDS-PAGE (FIG. 6).
Example 2
Characterization of the bifunctional molecule 2D-NBP8
[0055] The recombinant bifunctional protein 2D-NBP8 was analyzed by SDS-
PAGE and western blotting as previously described (Papanikolopoulou, K., et
al.
(2004) J. Biol. Chem. 279, 8991-8998). Briefly, 5p1/well of 100 pM 2D or 2D-
NBP8
was mixed with 4X SDS sample buffer (Novagen). The sample was boiled for 5 min
or kept at room temperature (RT) before loading onto a 10-20% Tricine-Glycine
gel
(Invitrogen). The electrophoresis was conducted in SDS-PAGE running buffer
with
125V constant voltage at 4 C. The gels were stained with SimplyBlue SafeStain
(Invitrogen). In western blot the anti-human CD4 polyclonal antibody (Immuno
#7301) and anti-NBP8 polyclonal antibody were used. As expected, the results
showed 2D-NBP8 had a molecular weight of about 30KD and could be detected by
both specific antibodies. (FIG. 6)
[0056] The recombinant bifunctional protein 2D-NBP8 was analyzed by ELISA
as previously described (Jiang, S. et al. 1998. J. Virol. 72:10213-10217).
Briefly, the
2D and 2D-NBP8 was coated to a 96-well polystyrene plate (Costar) (10 pg/m1 in
0.1M Tris-Hcl, pH 8.8) and blocked with 2% non-fat milk in PBS. The plate was
then
incubated with polyclonal antibodies against CD4 (T4-4), conformation-
dependent
monoclonal antibody against CD4 (Sim.4) and anti-NBP8 polyclonal antibody for
60
min and the horseradish peroxidase (HRP) secondary antibodies (ZYMED
Laboratories) were added. The plate was washed with the washing buffer (PBS
containing 0.01 % Tween 20) for 5 times. The substrate 3,3',5,5'-
tetramethylbenzidine
(TMB) (Sigma) was added sequentially. Absorbance at 450 nm (A450) was
measured using an ELISA reader (Ultra 384, Tecan). As expected, the results
showed soluble 2D-NBP8 could be detected by all the specific antibodies.
(FIGs. 7-
8)
14
WO 2011/140092 PCT/US2011/035007
Example 3
Binding of 2D-NBP8 to q020 and NHR as shown by ELISA
[0057] The binding of 2D-NBP8 to gp120 and NHR was detected by ELISA as
previously described (Huang JH et al. 2006. FEBS Letter. 580:4807-14).
Briefly, the
testing proteins were coated to a 96-well polystyrene plate (10 pg/ml in O.1 M
Tris-
Hcl, pH 8.8) and blocked with 2% non-fat milk in PBS. The plate was then
incubated
with biotinylated gp120 or 5-helix 2 pg/ml in PBS) at 37 C for 30 min. The
plate was
washed with the washing buffer (PBS containing 0.01 % Tween 20) five times.
Then,
the plate was incubated with horseradish peroxidase (HRP) labeled with
streptavidin
(SA-HRP) (ZYMED Laboratories) and the plate was washed five times. The
substrate TMB was then added and absorbance at 450 nm (A450) was measured
using an ELISA reader. As shown in FIGs. 9-10, functional binding was detected
between 2D-NBP8 and gp120 and between 2D-NBP8 and 5-helix (a mimic NHR
molecule).
Example 4
Binding of 2D-NBP8 to natural q0 20/=41 on cell surface as detected by flow
cytometry
[0058] The binding of 2D-NBP8 to natural gpl20/gp4l on cell surface was
detected by flow cytometry as previously described (Jiang S. et al.). Briefly,
CHO-EE
(no Env) and CHO-WT (has Env) were detached and washed with wash buffer (PBS
containing 5% GBS) three times. Then they were incubated with the testing
protein
for 1 hr at 4 C. After three washes, anti-human CD4 polyclonal antibody
(Immuno
#7301) and anti-NBP8 polyclonal antibody were added for 1 hr at 4 C. After
three
washes, FITC-conjugated anti-rabbit or mouse antibody were added and incubated
for 1 hr at 4 C. After at least three washings, the cells were examined by
flow
cytometry and the fluorescence intensity was recorded by FACSCalibur (Becton
Dickinson). As shown in FIG. 11, 2D-NBP8 can functionally bind to the native
HIV
Env expressed on the effector cells as sCD4.
WO 2011/140092 PCT/US2011/035007
Example 5
Binding affinity of 2D-NBP8 to gp120 as measured by SPR
[0059] The binding affinity of 2D-NBP8 to gp120 was measured by surface
plasmon resonance (SPR) using BlAcore3000 system (Pharmacia), following the
Biomolecular Interaction Analysis (BIA) Technology Manual as previously
described
(Lu, L et al. Journal of Biological Chemistry 283:16723-16731). Briefly, gp120
(100
pg/ml) was immobilized onto the CM5 sensor chip by amine coupling, and the
unreacted sites were blocked with ethanolamine. The association reaction was
initiated by injecting 35pl protein sample at a flow rate of 5p1/min. The
dissociation
reaction was done by washing with running buffer (10mM HEPES pH7.4 containing
0.15M NaCl, 3.4mM EDTA and 0.005% v/v Surfactant) for at least 2 min. As shown
in FIG. 12 and Table 2, the recombinant 2D-NBP8 protein has high affinity to
gp120
(KD 1.9e10-8).
16
WO 2011/140092 PCT/US2011/035007
Table 2
Protein Ka Kd KA KD
M-1 S-1 S-1 M-1 M
T1144 2.8 e3 5.2 e3 5.4 e5 1.8 e6
GP120+ 2D 2.2 e4 4.7 e4 4.8 e7 2.1 e-$
2D-NBP8 2.5 e4 4.8 e4 5.2 e7 1.9 e-8
Example 6
2D-NBP8 inhibits 6-helix bundle formation
[0060] The ability of 2D-NBP8 to prevent 6-HB formation was determined by
ELISA and FN-PAGE using a fluorescence C34-FAM probe as previously described
(Liu SW et al. 2005 JBC 280:12, 11259-11273). Briefly, a testing peptide was
pre-
incubated with equal amount of N36 at 37 C for 30 min, followed by the
addition of
C34-biotin (0.5 pM). The mixture was added to a 96-well polystyrene plate
coated
with mAb NC-1 IgG (2 pg/ml in O.1 M Tris, pH 8.8) and blocked with 2% non-fat
milk
in PBS. The plate was then incubated for 30 min and SA-HRP was added. The
plate
was washed with the washing buffer (PBS containing 0.01% Tween 20) six times
to
remove any unbound peptide. The substrate TMB was added and the absorbance at
450 nm (A450) was measured using an ELISA reader. The percent inhibition of 6-
HB
formation and the IC50 values were calculated using the CalcuSyn software.
[0061] In the FN-PAGE assay, a testing peptide was preincubated with an equal
amount of N36 at 37 C for 30 min, followed by the addition of C34-FAM at 37 C
for
30 min. And then the mixtures were added into Tris-glycine native sample
buffer
(Invitrogen). The samples (20 pl) were then loaded onto Tris-glycine gels
(18%),
which were run under 120 V constant voltage at room temperature for 1 hrs. The
gels were stained visualized with the FluorChem 8800 Imaging System (Alpha
Innotech Corp.) using a transillumination UV light source with excitation
wavelength
at 520 nm and then stained with Coomassie blue.
[0062] As shown in FIG. 13, 2D-NBP8 could strongly inhibit N36/C34 6-HB
formation like T1144, while 2D was ineffective in blocking the 6-HB formation.
The
result was further confirmed in FN-PAGE assay. With an increase in
concentration
17
WO 2011/140092 PCT/US2011/035007
(from 1 pM to 10 pM), 2D-NBP8 was able to prevent C34-FAM/N36 6-HB formation
completely (FIG. 14).
Example 7
Inhibitory activity of 2D-NBP8 on HIV-1-mediated cell-cell fusion and HIV-1
replication
[0063] HIV-1-mediated cell-cell fusion was determined by a dye transfer assay
(Lu H et al. J Virol Methods 107:155-161, 2003.) using Calcein AM-labeled HIV-
11118
chronically infected H9 (H9/HIV-1 IIIB) cells as effector cells and MT-2 cells
as target
cells. The percent inhibition of cell-cell fusion by the chimeras was
calculated, and
50% inhibitory concentration (IC50) was calculated using the CalcuSyn
software. As
shown in Table 3, 2D-NBP8 was highly effective in inhibiting HIV-1 -mediated
cell-cell
fusion with IC50 (19.03 nM) at low nM level.
[0064] The inhibitory activity of the bifunctional molecule on HIV-1 IIIB
infection
was determined by ELISA for p24 production (Jiang S et al. J Exp Med 174:1557-
1563, 1991). Briefly, MT-2 cells were infected with HIV-1111B at 100 TCID50
(50%
tissue culture infective dose) in RPMI 1640 medium containing 10% FBS in the
presence or absence of an antigen specific antiserum or IgG antibody in serial
2-fold
dilutions at 37 C overnight. The culture supernatants were then removed and
fresh
media were added. On day 4 post-infection, the culture supernatants were
collected
and mixed with equal volumes of 5% Triton X-1 00 for the detection in the p24
protein
ELISA. 2D-NBP8 was also highly potent in inhibiting HIV-1 IIIB infection with
IC50 at
5.64 nM, more than 3-fold better than T20 (FIG. 15 and Table 3).
[0065] For inhibition of infection by the M-tropic HIV-1 strain Bat (subtype
B, R5),
100 p1 of TZM-b1 cells (1 x105/m1) were pre-cultured overnight and infected
with Bat at
100 TCID50 in the presence or absence of the test peptide overnight. The cells
were
harvested and lysed on the fourth day post-infection with 50p1 of lysing
reagent. The
luciferase activity was analyzed using a luciferase kit (Promega) and a
luminometer
(Ultra 386, Tecan) according to the manufacturer's instruction. The percent
inhibition
of luciferase activity was calculated. As shown in FIG. 16 and Table 3, 2D-
NBP8 was
also highly potent in inhibiting HIV-1 IIIB infection with IC50 at 10.78 nM,
much better
than T20.
18
WO 2011/140092 PCT/US2011/035007
[0066] The inhibitory activity of the bifunctional molecule on infection by
primary
HIV-1 isolates, 92US657 (B, R5), 94UG103 (A, X4R5), 93MW959 (C, R5), RU570
(G, R5) and 92TH009 (E/A, R5) was determined (Jiang S et al. Antimicrob Agents
Chemother 48:4349-4359, 2004). Briefly, peripheral blood mononuclear cells
(PBMCs) were isolated from the blood of healthy donors using a standard
density
gradient (Histopaque-1077, Sigma) centrifugation. After incubation at 37 C for
2 hr,
the nonadherent cells were collected and resuspended at 5x105/ml in RPMI 1640
medium containing 10% FBS, 5 g of phytohemagglutinin (PHA)/ml, and 100 U of
IL-
2/ml, followed by incubation at 37 C for 3 days. The PHA-stimulated cells were
infected with the corresponding primary HIV-1 isolates at a multiplicity of
infection
(MOI) of 0.01 in the absence or presence of antisera at a serial 2-fold
dilution. The
supernatants were collected 7 days post-infection and tested for p24 antigen
by
ELISA as described above. The IC50 was calculated using the CalcuSyn software
as
described above. As shown in Table 3, 2D-NBP8 significantly inhibited
infection by
all the primary HIV-1 isolates in with IC50 at low nM level.
Table 3. Inhibitory activity of the peptides and recombinant proteins on HIV-1-
mediated cell-cell fusion and HIV-1 replication
2D 2D-NBP8 T20 T1144
Concentration (nM) I C50 I C90 I C50 I C90 I C50 I C90 I C50 I C90
HIV-1 IIIB-mediated cell fusion
97.83 137.18 19.03 46.51 20.15 41.71 5.89 15.26
HIV-1 replication
IIIB (B, X4) 56.80 246.02 5.64 28.79 17.26 117.21 2.13 35.23
Bal(B, R5) 170.20 >250 10.78 44.35 43.35 >250 4.03 28.11
92US657 (B, R5) >250 >250 17.17 51.85 56.07 223.92 ND ND
94UG103 (A,X4R5)* >250 >250 14.53 59.83 6.67 29.43 ND ND
93MW959 (C,R5)* >250 >250 18.93 48.86 4.70 18.76 ND ND
RU570 (G,R5)* >250 >250 55.58 146.39 44.08 109.66 ND ND
92TH009 (E/A,R5)* 25.30 113.69 17.50 71.93 1.43 7.99 ND ND
*Primary HIV-1 isolates
19
WO 2011/140092 PCT/US2011/035007
Example 8
Inactivation of HIV isolates by 2D-NBP8
[0067] Virus inactivation by 2D-NBP8 was determined by ELISA for p24
production or luciferase kit. Briefly, HIV-1 isolate (500 TCID50/ml) was added
to 100
pl of the samples with different concentration and incubate on 4 C for 1 hour.
Then,
PEG 6000 was added to the final concentration of 3% and centrifuge on a
microfuge
at 15,000 rpm for 30 min. The supernatants were removed, and the pellet was
washed with PBS and resuspended to 100 pl. MT-2 or TZM-bl cells (1 x 105 /ml)
were added at 100 pl/well, and cultured at 37 C for 3 days. p24 production in
MT-2
or luciferase activity was determined according to kit manufacturer'
instruction.
Results shown in FIG. 17-18 indicate that 2D-NBP8 in a dose-dependent manner
rapidly inactivates HIV-1 IIIB, an X4 virus and HIV-1 Bal, an R5 virus. In
contrast,
there were no significant effects on virus within a concentration range tested
in the
T20 and T1144 group.
Example 9
Inhibitory activity of the 2D-NBP1 and 2D-FBP1 on HIV-1-mediated cell-cell
fusion
and HIV-1 replication 2D-NBP8
[0068] The inhibitory activity of the 2D-NBP1 and 2D-FBP1 on HIV-1-mediated
cell-cell fusion and infection by the HIV-1 strains Bal and IIIB were
determined as
described above. As shown in the Table 4, both 2D-NBP1 and 2D-FBP1 were
effective in inhibiting HIV-1-mediated cell-cell fusion and HIV-1 replication,
suggesting that the NHR-binding peptide and the fusion peptide-binding peptide
linked to 2D or CD4 molecule retain their anti-HIV-1 activity.
Table 4. Inhibitory activity of the recombinant proteins on HIV-1-mediated
cell-cell
fusion and HIV-1 replication
EC50 (nM) for inhibiting infection by
Bal (B, R5) IIIB (B, X4) Cell-cell fusion
2D-NBP1 192.2 291.8 289.4
2D-FBP1 67.87 205.2 111.3
WO 2011/140092 PCT/US2011/035007
Example 10
Inactivation of HIV isolates by 2D-NBP1 and 2D-FBP1
[0069] Inactivation of the cell-free HIV-1 strains Bal and IIIB by 2D-NBP1 and
2D-FBP1 was detected as described above. As shown in the Table 5, both 2D-NBP1
and 2D-FBP1 could significantly inactivate the viruses with EC50 in the range
of 80-
300 nM, confirming that the recombinant proteins consisting of 2D or CD4 fused
with
the NHR-binding peptide and the fusion peptide-binding peptide linked to
molecule
are effective HIV-1 inactivators.
Table 5. Inactivation of cell-free HIV-1 R5 and X4 strains
EC50 (nM) for inhibiting infection by
Bal (B, R5) IIIB (B, X4)
2D-NBP1 299.12 173.46
2D-FBP1 169.21 81.25
Example 11
The potential mechanism of virus inhibition by 2D-NBP8
[0070] 2D-NBP8 can destabilize and inactivate the 2D-activated envelope
glycoprotein intermediate through interacting with exposed N-HR domain. To
measure the effects of 2D-NBP8 on HIV-1 envelope glycoprotein, an ELISA-based
system that utilizes live cells as a platform for expression of membrane-bound
trimeric envelope glycoprotein complexes was used as previously described
(Haim H
et al. Plos pathogens. 5:4, 1-13, 2009). Briefly, CHO-WT cells steadily
expressing
HIV-1 Env were seeded in 96-well plates (5x104 per well) and cultured at 37 C.
Two
days later, the cells were washed twice with blocking buffer (35 mg/ml BSA, 10
mg/ml non-fat dry milk, 1.8 mM CaCl2, 1 mM MgCl2, 25 mM Tris, pH 7.5 and 140
mM
NaCI). For pulse activation experiments, the cells were incubated with 2D (2.5
pM) or
21
WO 2011/140092 PCT/US2011/035007
2D-NBP8 (2.5 pM) suspended in blocking buffer for three minutes, washed three
times with blocking buffer and incubated for different time periods with C34-
biotin (at
2 pM for 30 minutes). To study the temperature dependence of HR1 groove
exposure, the 2D-pulsed cells were incubated at the requisite temperature for
different lengths of time; the cells were subsequently returned to room
temperature
for incubation with C34-biotin. Cells were then washed four times with
blocking buffer
and four times with washing buffer (140 mM NaCl, 1.8 mM CaCl2, 1 mM MgCl2
and20 mM Tris, pH 7.5). SA-HRP was then incubated with the samples for 45
minutes at RT. Cells were washed 5 times with blocking buffer and five times
with
washing buffer. HRP enzyme activity was determined after the addition of 33 pl
per
well of a 1:1 mix of Western Lightning oxidizing and luminol reagents (Perkin
Elmer
Life Sciences) supplemented with 150 mM NaCl. Light emission was measured.
[0071] Using above method, Haim et al. (PLoS. Pathog. 5:e1000360, 2009)
found the sCD4 and CD4-mimetic compounds significantly enhanced the binding of
the C34 to the HIV-1 envelope glycoprotein, which suggested the exposure of
the
NHR groove (C34 binding site) on Env after the sCD4 pulse. And importantly,
their
results showed the stability of the sCD4-activated NHR exposed intermediate
was
closely related to HIV-1 infectivity after activation by sCD4, especially the
HIV-1
infection of CD4-/CCR5+ cells which can be enhanced after sCD4 and CD4-mimetic
compounds. As shown in FIG. 19, 2D-NBP8 could significantly destabilize and
inactivate the 2D-activated Env fusion intermediate through interacting with
exposed
NHR groove induced by 2D.
Example 12
2D-NBP8 can significantly reduce the enhancement effects of CD4-related on the
HIV-1 infection of the CD4-/CCR5+ cells
[0072] Soluble sCD4 has been shown to modestly enhance HIV-1 infection of
CD4-/CCR5+ cells (Haim H et al.). Since 2D-NBP8 contains the D1 D2 domain of
sCD4, it is necessary to investigate whether 2D-NBP8 could also HIV-1
infection of
CD4-/CCR5+ cells using the same method as described by Haim et al. Briefly,
Cf2Th-CCR5 cells (NIH ARRRP CN4662) (6x105 cells per well) and the virus (HIV-
1
Bal) were mixed in the presence of different concentrations of 2D and 2D-NBP8
in
22
WO 2011/140092 PCT/US2011/035007
the culture medium and infectivity was measured three days later. The results
showed that 2D enhanced virus infection in some concentration ranges, while 2D-
NBP8 did not enhance, but rather significantly suppressed, the enhancement
effects
of CD4-related on the HIV-1 infection of the CD4-/CCR5+ (FIG. 20).
Table 6. Sequences of components of the bifunctional HIV entry inhibitors
Molecule SEQ ID
NO Sequence
2D-NBP (source of NBP)
2D-NBP1 37 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(C46) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7WMEWDREINNYTSLIHSLI
EESQNQQEKNEQELLELDKWASLWNWF
2D-NBP2 38 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(C38) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7TTWMEWDREINNYTSLIH
SLIEESQNQQEKNEQELLEL
2D-NBP3 39 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(C36) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7WMEWDREINNYTSLIHSLI
EESQNQQEKNEQELLEL
2D-NBP4 40 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(C34) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7WMEWDREINNYTSLIHSLI
EESQNQQEKNEQELL
2D-NBP5 41 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(C28) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7WMEWDREINNYTSLIHSLI
EESQNQQEK
2D-NBP6 42 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(C51) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7WMEWDREINNYTSLIHSLI
EESQNQQEKNEQELLELDKWASLWNWF
23
WO 2011/140092 PCT/US2011/035007
Molecule SEQ ID
NO Sequence
2D-NBP7 43 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(sifuvirtide) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7SWETWEREIENYTKQIYKI
LEESQEQQDRNEKDLLE
2D-NBP8 44 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(T1144) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VE FKI D IVVLAFQ KASS I (G GG GS)7TTWEAWD RAIAEYAARI E
ALLRALQEQQEKNEAALREL
2D-NBP9 45 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(C35-EK) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7WEEWDKKIEEYTKKIEELI
KKSEEQQKKNEEELKK
2D-NBP10 46 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(CP621-652) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7QIWNNMTWMEWDREINN
YTSLIHSLIEESQNQ
2D-NBP11 47 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(CP32M) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7VENETWMEWEREIENYT
KLIYKILEESQEQ
2D-NBP12 48 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(T1249) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7WQEWEQKITALLEQAQIQ
QEKNEYELQKLDKWASLWEWF
2D-NBP13 49 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(PBD-4HR) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7WMEWDREIEEYTKKIEEY
TKKI EEYTKKI EEYTKKI
2D-NBP14 50 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(CBD1) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7SLEQIWNNMTWMQWDK
24
WO 2011/140092 PCT/US2011/035007
Molecule SEQ ID
NO Sequence
2D-NBP15 51 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(T20) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7YTSLIHSLIEESQNQQEKN
EQELLELDKWASLWNWF
2D-CBP (source of CBP)
2D-CBP1 52 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(N46) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7TLTVQARQLLSGIVQQQN
N LLRAI EAQQH LLQLTVWG I KQLQARI L
2D-CBP2 53 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(N36) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7SGIVQQQNNLLRAIEAQQ
HLLQLTVWGIKQLQARIL
2D-CBP3 54 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(N34) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7SGIVQQQNNLLRAIEAQQ
HLLQLTVWGIKQLQAR
2D-CBP4 55 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(N51) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIWLAFQKASS(GGGGS)7QARQLLSGIVQQQNNLLR
AI EAQQH LLQLTVWGI KQLQARI LAVERYLKQQ
2D-CBP5 56 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(DP-107) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7NNLLRAIEAQQHLLQLTV
WGI KQLQARI LAVERYLKDQ
2D-CBP6 57 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(N 17) FLTKGPSKLNDRAIDS RRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7LLQLTVWGIKQLQARIL
2D-CBP7 58 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(N28) FLTKGPSKLNDRAIDS RRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7IEAQQHLLQLTVWGIKQL
QARI LAV E RY
WO 2011/140092 PCT/US2011/035007
Molecule SEQ ID
NO Sequence
2D-FBP (source of FBP)
2D-FBP1 59 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(VIRIP164) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7LEAIPCSIPPCVFFNKPFV
F
2D-FBP2 60 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(VIRIP165) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7LEAIPCSIPPCVFANKPFV
F
2D-FBP3 61 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(VIRIP353) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7LEAIPCSIPPCFLFNKPFVF
2D-FBP4 62 KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGS
(VIRIP576) FLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICE
VEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPS
VQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKK
VEFKIDIVVLAFQKASSI(GGGGS)7LEAIPCSIPPEFLFGKPFVF
[0073] Unless otherwise indicated, all numbers expressing quantities of
ingredients, properties such as molecular weight, reaction conditions, and so
forth
used in the specification and claims are to be understood as being modified in
all
instances by the term "about." Accordingly, unless indicated to the contrary,
the
numerical parameters set forth in the specification and attached claims are
approximations that may vary depending upon the desired properties sought to
be
obtained by the present invention. At the very least, and not as an attempt to
limit
the application of the doctrine of equivalents to the scope of the claims,
each
numerical parameter should at least be construed in light of the number of
reported
significant digits and by applying ordinary rounding techniques.
Notwithstanding that
the numerical ranges and parameters setting forth the broad scope of the
invention
are approximations, the numerical values set forth in the specific examples
are
reported as precisely as possible. Any numerical value, however, inherently
contains certain errors necessarily resulting from the standard deviation
found in
their respective testing measurements.
26
WO 2011/140092 PCT/US2011/035007
[0074] The terms "a," "an," "the" and similar referents used in the context of
describing the invention (especially in the context of the following claims)
are to be
construed to cover both the singular and the plural, unless otherwise
indicated herein
or clearly contradicted by context. Recitation of ranges of values herein is
merely
intended to serve as a shorthand method of referring individually to each
separate
value falling within the range. Unless otherwise indicated herein, each
individual
value is incorporated into the specification as if it were individually
recited herein. All
methods described herein can be performed in any suitable order unless
otherwise
indicated herein or otherwise clearly contradicted by context. The use of any
and all
examples, or exemplary language (e.g., "such as") provided herein is intended
merely to better illuminate the invention and does not pose a limitation on
the scope
of the invention otherwise claimed. No language in the specification should be
construed as indicating any non-claimed element essential to the practice of
the
invention.
[0075] Groupings of alternative elements or embodiments of the invention
disclosed herein are not to be construed as limitations. Each group member may
be
referred to and claimed individually or in any combination with other members
of the
group or other elements found herein. It is anticipated that one or more
members of
a group may be included in, or deleted from, a group for reasons of
convenience
and/or patentability. When any such inclusion or deletion occurs, the
specification is
deemed to contain the group as modified thus fulfilling the written
description of all
Markush groups used in the appended claims.
[0076] Certain embodiments of this invention are described herein, including
the
best mode known to the inventors for carrying out the invention. Of course,
variations on these described embodiments will become apparent to those of
ordinary skill in the art upon reading the foregoing description. The inventor
expects
skilled artisans to employ such variations as appropriate, and the inventors
intend for
the invention to be practiced otherwise than specifically described herein.
Accordingly, this invention includes all modifications and equivalents of the
subject
matter recited in the claims appended hereto as permitted by applicable law.
Moreover, any combination of the above-described elements in all possible
27
WO 2011/140092 PCT/US2011/035007
variations thereof is encompassed by the invention unless otherwise indicated
herein
or otherwise clearly contradicted by context.
[0077] Furthermore, numerous references have been made to patents and
printed publications throughout this specification. Each of the above-cited
references and printed publications are individually incorporated herein by
reference
in their entirety.
[0078] In closing, it is to be understood that the embodiments of the
invention
disclosed herein are illustrative of the principles of the present invention.
Other
modifications that may be employed are within the scope of the invention.
Thus, by
way of example, but not of limitation, alternative configurations of the
present
invention may be utilized in accordance with the teachings herein.
Accordingly, the
present invention is not limited to that precisely as shown and described.
28
SEQUENCE LISTING IN ELECTRONIC FORM
In accordance with Section 111(1) of the Patent Rules, this description
contains a sequence listing in electronic form in ASCII text format (file:
51432-151 SEQ 19-10-2012 vl.txt).
A copy of the sequence listing in electronic form is available from the
Canadian Intellectual Property Office.
The sequences in the sequence listing in electronic form are reproduced in
the following table.
SEQUENCE TABLE
<110> Jiang, Shibo
Pan, Chungen
Lu, Lu
<120> Bifunctional Molecules for Inactivating HIV and Blocking HIV
Entry
<130> 1958427-00168
<150> 61/330,787
<151> 2010-05-03
<160> 64
<170> Patentln version 3.5
<210> 1
<211> 36
<212> PRT
<213> Human immunodeficiency virus
<400> 1
Ser Gly Ile Val Gln Gln Gln Asn Asn Leu Leu Arg Ala Ile Glu Ala
1 5 10 15
Gln Gln His Leu Leu Gln Leu Thr Val Trp Gly Ile Lys Gln Leu Gln
20 25 30
Ala Arg Ile Leu
<210> 2
<211> 28
<212> PRT
<213> Human immunodeficiency virus
<400> 2
Ile Glu Ala Gln Gln His Leu Leu Gln Leu Thr Val Trp Gly Ile Lys
1 5 10 15
29
Gin Leu Gin Ala Arg Ile Leu Ala Val Glu Arg Tyr
20 25
<210> 3
<211> 57
<212> PRT
<213> Human immunodeficiency virus
<400> 3
Met Gly Ala Ala Ser Met Thr Leu Thr Val Gin Ala Arg Gin Leu Leu
1 5 10 15
Ser Gly Ile Val Gin Gin Gin Asn Asn Leu Leu Arg Ala Ile Glu Ala
20 25 30
Gin Gin His Leu Leu Gin Leu Thr Val Trp Gly Ile Lys Gin Leu Gin
35 40 45
Ala Arg Ile Leu Ala Val Glu Arg Tyr
50 55
<210> 4
<211> 34
<212> PRT
<213> Human immunodeficiency virus
<400> 4
Leu Leu Glu Gin Glu Asn Lys Glu Gin Gin Asn Gin Ser Glu Glu Ile
1 5 10 15
Leu Ser His Ile Leu Ser Thr Tyr Asn Asn Ile Glu Arg Asp Trp Glu
20 25 30
Met Trp
<210> 5
<211> 36
<212> PRT
<213> Human immunodeficiency virus
<400> 5
Phe Trp Asn Trp Leu Ser Ala Trp Lys Asp Leu Glu Leu Leu Glu Gin
1 5 10 15
Glu Asn Lys Glu Gin Gin Asn Gin Ser Glu Glu Ile Leu Ser His Ile
20 25 30
Leu Ser Thr Tyr
<210> 6
<211> 46
<212> PRT
<213> Human immunodeficiency virus
<400> 6
Trp Met Glu Trp Asp Arg Glu Ile Asn Asn Tyr Thr Ser Leu Ile His
1 5 10 15
Ser Leu Ile Glu Glu Ser Gin Asn Gin Gin Glu Lys Asn Glu Gin Glu
20 25 30
Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe
35 40 45
<210> 7
<211> 38
<212> PRT
<213> Human immunodeficiency virus
<400> 7
Thr Thr Trp Met Glu Trp Asp Arg Glu Ile Asn Asn Tyr Thr Ser Leu
1 5 10 15
Ile His Ser Leu Ile Glu Glu Ser Gln Asn Gln Gln Glu Lys Asn Glu
20 25 30
Gln Glu Leu Leu Glu Leu
<210> 8
<211> 36
<212> PRT
<213> Human immunodeficiency virus
<400> 8
Trp Met Glu Trp Asp Arg Glu Ile Asn Asn Tyr Thr Ser Leu Ile His
1 5 10 15
Ser Leu Ile Glu Glu Ser Gin Asn Gln Gln Glu Lys Asn Glu Gln Glu
20 25 30
Leu Leu Glu Leu
<210> 9
<211> 28
<212> PRT
<213> Human immunodeficiency virus
<400> 9
Trp Met Glu Trp Asp Arg Glu Ile Asn Asn Tyr Thr Ser Leu Ile His
1 5 10 15
Ser Leu Ile Glu Glu Ser Gln Asn Gln Gln Glu Lys
20 25
<210> 10
<211> 46
<212> PRT
<213> Human immunodeficiency virus
<400> 10
Trp Met Glu Trp Asp Arg Glu Ile Asn Asn Tyr Thr Ser Leu Ile His
1 5 10 15
Ser Leu Ile Glu Glu Ser Gln Asn Gln Gln Glu Lys Asn Glu Gln Glu
20 25 30
Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe
35 40 45
31
<210> 11
<211> 36
<212> PRT
<213> Human immunodeficiency virus
<400> 11
Ser Trp Glu Thr Trp Glu Arg Glu Ile Glu Asn Tyr Thr Lys Gin Ile
1 5 10 15
Tyr Lys Ile Leu Glu Glu Ser Gin Glu Gin Gin Asp Arg Asn Glu Lys
20 25 30
Asp Leu Leu Glu
<210> 12
<211> 38
<212> PRT
<213> Human immunodeficiency virus
<400> 12
Thr Thr Trp Glu Ala Trp Asp Arg Ala Ile Ala Glu Tyr Ala Ala Arg
1 5 10 15
Ile Glu Ala Leu Leu Arg Ala Leu Gin Glu Gin Gin Glu Lys Asn Glu
20 25 30
Ala Ala Leu Arg Glu Leu
<210> 13
<211> 32
<212> PRT
<213> Human immunodeficiency virus
<400> 13
Gin Ile Trp Asn Asn Met Thr Trp Met Glu Trp Asp Arg Glu Ile Asn
1 5 10 15
Asn Tyr Thr Ser Leu Ile His Ser Leu Ile Glu Glu Ser Gin Asn Gin
20 25 30
<210> 14
<211> 30
<212> PRT
<213> Human immunodeficiency virus
<400> 14
Val Glu Asn Glu Thr Trp Met Glu Trp Glu Arg Glu Ile Glu Asn Tyr
1 5 10 15
Thr Lys Leu Ile Tyr Lys Ile Leu Glu Glu Ser Gin Glu Gin
20 25 30
<210> 15
<211> 39
<212> PRT
<213> Human immunodeficiency virus
32
<400> 15
Trp Gin Glu Trp Glu Gin Lys Ile Thr Ala Leu Leu Glu Gin Ala Gin
1 5 10 15
Ile Gin Gin Glu Lys Asn Glu Tyr Glu Leu Gin Lys Leu Asp Lys Trp
20 25 30
Ala Ser Leu Trp Glu Trp Phe
<210> 16
<211> 36
<212> PRT
<213> Human immunodeficiency virus
<400> 16
Trp Met Glu Trp Asp Arg Glu Ile Glu Glu Tyr Thr Lys Lys Ile Glu
1 5 10 15
Glu Tyr Thr Lys Lys Ile Glu Glu Tyr Thr Lys Lys Ile Glu Glu Tyr
20 25 30
Thr Lys Lys Ile
<210> 17
<211> 16
<212> PRT
<213> Human immunodeficiency virus
<400> 17
Ser Leu Glu Gin Ile Trp Asn Asn Met Thr Trp Met Gin Trp Asp Lys
1 5 10 15
<210> 18
<211> 46
<212> PRT
<213> Human immunodeficiency virus
<400> 18
Thr Leu Thr Val Gin Ala Arg Gin Leu Leu Ser Gly Ile Val Gin Gin
1 5 10 15
Gin Asn Asn Leu Leu Arg Ala Ile Glu Ala Gin Gin His Leu Leu Gin
20 25 30
Leu Thr Val Trp Gly Ile Lys Gin Leu Gin Ala Arg Ile Leu
35 40 45
<210> 19
<211> 34
<212> PRT
<213> Human immunodeficiency virus
<400> 19
Ser Gly Ile Val Gin Gin Gin Asn Asn Leu Leu Arg Ala Ile Glu Ala
1 5 10 15
Gin Gin His Leu Leu Gin Leu Thr Val Trp Gly Ile Lys Gin Leu Gin
20 25 30
33
Ala Arg
<210> 20
<211> 51
<212> PRT
<213> Human immunodeficiency virus
<400> 20
Gin Ala Arg Gin Leu Leu Ser Gly Ile Val Gin Gin Gin Asn Asn Leu
1 5 10 15
Leu Arg Ala Ile Glu Ala Gin Gin His Leu Leu Gin Leu Thr Val Trp
20 25 30
Gly Ile Lys Gin Leu Gin Ala Arg Ile Leu Ala Val Glu Arg Tyr Leu
35 40 45
Lys Gin Gin
<210> 21
<211> 38
<212> PRT
<213> Human immunodeficiency virus
<400> 21
Asn Asn Leu Leu Arg Ala Ile Glu Ala Gin Gin His Leu Leu Gin Leu
1 5 10 15
Thr Val Trp Gly Ile Lys Gin Leu Gin Ala Arg Ile Leu Ala Val Glu
20 25 30
Arg Tyr Leu Lys Asp Gin
<210> 22
<211> 17
<212> PRT
<213> Human immunodeficiency virus
<400> 22
Leu Leu Gin Leu Thr Val Trp Gly Ile Lys Gln Leu Gin Ala Arg Ile
1 5 10 15
Leu
<210> 23
<211> 20
<212> PRT
<213> Human immunodeficiency virus
<400> 23
Leu Glu Ala Ile Pro Cys Ser Ile Pro Pro Cys Val Phe Phe Asn Lys
1 5 10 15
Pro Phe Val Phe
34
<210> 24
<211> 19
<212> PRT
<213> Human immunodeficiency virus
<400> 24
Leu Glu Ala Ile Pro Cys Ser Ile Pro Pro Cys Val Phe Ala Asn Lys
1 5 10 15
Pro Phe Val
<210> 25
<211> 20
<212> PRT
<213> Human immunodeficiency virus
<400> 25
Leu Glu Ala Ile Pro Cys Ser Ile Pro Pro Cys Phe Leu Phe Asn Lys
1 5 10 15
Pro Phe Val Phe
<210> 26
<211> 20
<212> PRT
<213> Human immunodeficiency virus
<400> 26
Leu Glu Ala Ile Pro Cys Ser Ile Pro Pro Glu Phe Leu Phe Gly Lys
1 5 10 15
Pro Phe Val Phe
<210> 27
<211> 42
<212> DNA
<213> Artificial Sequence
<220>
<223> Forward primer for amplification of 2D
<400> 27
cgcggatccc atcaccatca ccatcataag aaagtggtgc tg 42
<210> 28
<211> 37
<212> DNA
<213> Artificial Sequence
<220>
<223> Reverse primer for amplification of 2D
<400> 28
cacttcctcc tcctcctatg ctggaggcct tctggaa 37
<210> 29
<211> 81
<212> DNA
<213> Artificial Sequence
<220>
<223> Forward linker for amplification of 35-mer linker
<400> 29
ggaggaggag gaagtggcgg cggcggctcg ggtggtggtg gttctggagg tggcggtagc 60
ggaggtggag gtagtggagg c 81
<210> 30
<211> 79
<212> DNA
<213> Artificial Sequence
<220>
<223> Reverse primer for amplification of 35-mer linker
<400> 30
gctacctccg cctcccgaac ctccgcctcc actacctcca cctccgctac cgccacctcc 60
agaaccacca ccacccgag 79
<210> 31
<211> 86
<212> DNA
<213> Artificial Sequence
<220>
<223> Forward primer for amplification of NBP8
<400> 31
gaggcggagg tagcacgacc tgggaagcat gggacagagc tattgctgaa tacgcagcta 60
ggatagaagc tttactcaga gcttta 86
<210> 32
<211> 80
<212> DNA
<213> Artificial Sequence
<220>
<223> Reverse primer for amplification of NBP8
<400> 32
cggagatctc tataattccc ttaaggctgc ttcattcttt tcttgctgtt cttgtaaagc 60
tctgagtaaa gcttctatcc 80
<210> 33
<211> 185
<212> PRT
<213> Homo sapiens
36
CA 02794632 2012-10 29
<400> 33
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gln Lys Lys Ser Ile Gln Phe His Trp Lys Asn Ser Asn
20 25 30
Gln Ile Lys Ile Leu Gly Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gln Lys Glu Glu Val Gln Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gln Gly Gln
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gln Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gln Leu Glu Leu Gln Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gln Asn Gln Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gln Lys Ala Ser Ser Ile
180 185
<210> 34
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> 35-mer linker
<400> 34
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15
Gly Gly Gly Ser Giy Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
20 25 30
Gly Gly Ser
<210> 35
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> N-terminal amino acid sequence
<400> 35
Gly Pro Leu Gly Ser His His His His His His
1 5 10
37
CA 02794632 2012-10 29"
<210> 36
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> C-terminal amino acid sequence
<400> 36
Glu Phe Leu Glu Val Leu Phe Gln
1 5
<210> 37
<211> 266
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-NBP1
<400> 37
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gln Lys Lys Ser Ile Gln Phe His Trp Lys Asn Ser Asn
20 25 30
Gln Ile Lys Ile Leu Gly Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gln Lys Glu Glu Val Gln Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gln Gly Gln
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gln Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gln Leu Glu Leu Gin Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gln Asn Gln Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gln Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Trp Met Glu Trp
210 215 220
Asp Arg Glu Ile Asn Asn Tyr Thr Ser Leu Ile His Ser Leu Ile Glu
225 230 235 240
Glu Ser Gln Asn Gln Gln Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu
245 250 255
Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe
260 265
38
<210> 38
<211> 258
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-NBP2
<400> 38
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gln Lys Lys Ser Ile Gln Phe His Trp Lys Asn Ser Asn
20 25 30
Gln Ile Lys Ile Leu Gly Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gln Lys Glu Glu Val Gln Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gln Gly Gln
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gln Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gln Leu Glu Leu Gln Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gln Asn Gln Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gln Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Thr Thr Trp Met
210 215 220
Glu Trp Asp Arg Glu Ile Asn Asn Tyr Thr Ser Leu Ile His Ser Leu
225 230 235 240
Ile Giu Glu Ser Gin Asn Gln Gln Glu Lys Asn Glu Gln Glu Leu Leu
245 250 255
Glu Leu
<210> 39
<211> 256
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-NBP3
<400> 39
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gln Lys Lys Ser Ile Gln Phe His Trp Lys Asn Ser Asn
20 25 30
39
Gin Ile Lys Ile Leu Gly Asn Gin Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gin
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gin Lys Glu Glu Val Gin Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gin Gly Gin
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gin Cys Arg Ser Pro Arg Gly Lys Asn Ile Gin Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gin Leu Glu Leu Gin Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gin Asn Gin Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gin Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Trp Met Glu Trp
210 215 220
Asp Arg Glu Ile Asn Asn Tyr Thr Ser Leu Ile His Ser Leu Ile Glu
225 230 235 240
Glu Ser Gin Asn Gin Gin Glu Lys Asn Glu Gin Glu Leu Leu Glu Leu
245 250 255
<210> 40
<211> 254
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-NBP4
<400> 40
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gin Lys Lys Ser Ile Gin Phe His Trp Lys Asn Ser Asn
20 25 30
Gin Ile Lys Ile Leu Gly Asn Gin Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gin
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gin Lys Glu Glu Val Gin Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gin Gly Gin
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gin Cys Arg Ser Pro Arg Gly Lys Asn Ile Gin Gly Gly Lys Thr Leu
130 135 140
CA 027946322012-10 29 Ser Val Ser Gin Leu Glu Leu Gin Asp Ser Gly Thr Trp Thr
Cys Thr
145 150 155 160
Val Leu Gin Asn Gin Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gin Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Trp Met Glu Trp
210 215 220
Asp Arg Glu Ile Asn Asn Tyr Thr Ser Leu Ile His Ser Leu Ile Glu
225 230 235 240
Glu Ser Gin Asn Gin Gin Glu Lys Asn Glu Gin Glu Leu Leu
245 250
<210> 41
<211> 248
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-NBP5
<400> 41
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gin Lys Lys Ser Ile Gin Phe His Trp Lys Asn Ser Asn
20 25 30
Gin Ile Lys Ile Leu Gly Asn Gin Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gin
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gin Lys Glu Glu Val Gin Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gin Gly Gin
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gin Cys Arg Ser Pro Arg Gly Lys Asn Ile Gin Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gin Leu Glu Leu Gin Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gin Asn Gin Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gin Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Trp Met Glu Trp
210 215 220
Asp Arg Glu Ile Asn Asn Tyr Thr Ser Leu Ile His Ser Leu Ile Glu
225 230 235 240
Glu Ser Gin Asn Gin Gin Glu Lys
245
41
CA 027946322012-10 29
<210> 42
<211> 266
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-NBP6
<400> 42
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gln Lys Lys Ser Ile Gln Phe His Trp Lys Asn Ser Asn
20 25 30
Gln Ile Lys Ile Leu Gly Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gln Lys Glu Glu Val Gln Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gln Gly Gln
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gln Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gln Leu Glu Leu Gln Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gln Asn Gln Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gln Lys Ala Ser Ser Ile Giy Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Giy Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Trp Met Glu Trp
210 215 220
Asp Arg Glu Ile Asn Asn Tyr Thr Ser Leu Ile His Ser Leu Ile Glu
225 230 235 240
Glu Ser Gln Asn Gln Gln Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu
245 250 255
Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe
260 265
<210> 43
<211> 256
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-NBP7
<400> 43
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
42
Thr Ala Ser Gln Lys Lys Ser Ile Gln Phe His Trp Lys Asn Ser Asn
20 25 30
Gln Ile Lys Ile Leu Gly Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gin Lys Glu Glu Val Gln Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gln Gly Gln
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gln Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gln Leu Glu Leu Gln Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gln Asn Gln Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gln Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Trp Glu Thr
210 215 220
Trp Glu Arg Glu Ile Glu Asn Tyr Thr Lys Gln Ile Tyr Lys Ile Leu
225 230 235 240
Glu Glu Ser Gln Glu Gln Gln Asp Arg Asn Glu Lys Asp Leu Leu Glu
245 250 255
<210> 44
<211> 258
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-NBP8
<400> 44
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gln Lys Lys Ser Ile Gin Phe His Trp Lys Asn Ser Asn
20 25 30
Gln Ile Lys Ile Leu Gly Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Giu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gln Lys Glu Glu Val Gln Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gln Gly Gln
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
43
Gln Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gln Leu Glu Leu Gln Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gln Asn Gln Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gln Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Thr Thr Trp Glu
210 215 220
Ala Trp Asp Arg Ala Ile Ala Glu Tyr Ala Ala Arg Ile Glu Ala Leu
225 230 235 240
Leu Arg Ala Leu Gln Glu Gln Gln Glu Lys Asn Glu Ala Ala Leu Arg
245 250 255
Glu Leu
<210> 45
<211> 255
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-NBP9
<400> 45
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gln Lys Lys Ser Ile Gln Phe His Trp Lys Asn Ser Asn
20 25 30
Gin Ile Lys Ile Leu Gly Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gln Lys Glu Glu Val Gln Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gln Gly Gln
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gln Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gln Leu Glu Leu Gln Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gln Asn Gln Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gln Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Trp Glu Glu Trp
210 215 220
44
CA 027946322012-10 29
Asp Lys Lys Ile Glu Glu Tyr Thr Lys Lys Ile Glu Glu Leu Ile Lys
225 230 235 240
Lys Ser Glu Glu Gin Gin Lys Lys Asn Glu Glu Glu Leu Lys Lys
245 250 255
<210> 46
<211> 252
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-NBP10
<400> 46
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Her Gin Lys Lys Her Ile Gin Phe His Trp Lys Asn Her Asn
20 25 30
Gin Ile Lys Ile Leu Gly Asn Gin Gly Her Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Her Arg Arg Ser Leu Trp Asp Gin
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Her Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gin Lys Glu Glu Val Gin Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Her Asp Thr His Leu Leu Gin Gly Gin
100 105 110
Her Leu Thr Leu Thr Leu Glu Her Pro Pro Gly Her Her Pro Her Val
115 120 125
Gin Cys Arg Her Pro Arg Gly Lys Asn Ile Gin Gly Gly Lys Thr Leu
130 135 140
Her Val Her Gin Leu Glu Leu Gin Asp Her Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gin Asn Gin Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gin Lys Ala Her Her Ile Gly Gly Gly Gly Her Gly Gly
180 185 190
Gly Giy Her Gly Gly Giy Gly Her Gly Gly Gly Gly Her Gly Giy Gly
195 200 205
Gly Her Gly Gly Gly Gly Her Gly Gly Gly Gly Her Gin Ile Trp Asn
210 215 220
Asn Met Thr Trp Met Glu Trp Asp Arg Glu Ile Asn Asn Tyr Thr Her
225 230 235 240
Leu Ile His Her Leu Ile Glu Glu Her Gin Asn Gin
245 250
<210> 47
<211> 250
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-NBP11
CA 027946322012-10 29
<400> 47
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gin Lys Lys Ser Ile Gin Phe His Trp Lys Asn Ser Asn
20 25 30
Gin Ile Lys Ile Leu Gly Asn Gin Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gin
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gin Lys Glu Glu Val Gin Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gin Gly Gin
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gin Cys Arg Ser Pro Arg Gly Lys Asn Ile Gin Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gin Leu Glu Leu Gin Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gin Asn Gin Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gin Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Val Glu Asn Glu
210 215 220
Thr Trp Met Glu Trp Glu Arg Glu Ile Glu Asn Tyr Thr Lys Leu Ile
225 230 235 240
Tyr Lys Ile Leu Glu Glu Ser Gin Glu Gin
245 250
<210> 48
<211> 259
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino Acid sequence of NBP12
<400> 48
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gin Lys Lys Ser Ile Gin Phe His Trp Lys Asn Ser Asn
20 25 30
Gin Ile Lys Ile Leu Gly Asn Gin Gly Her Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Her Leu Trp Asp Gin
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gin Lys Glu Glu Val Gin Leu Leu
85 90 95
46
CA 027946322012-10 29
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gln Gly Gln
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gin Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gln Leu Glu Leu Gln Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gln Asn Gln Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gln Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Trp Gln Glu Trp
210 215 220
Glu Gln Lys Ile Thr Ala Leu Leu Glu Gln Ala Gln Ile Gln Gln Glu
225 230 235 240
Lys Asn Glu Tyr Glu Leu Gln Lys Leu Asp Lys Trp Ala Ser Leu Trp
245 250 255
Glu Trp Phe
<210> 49
<211> 256
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-NBP13
<400> 49
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gln Lys Lys Ser Ile Gln Phe His Trp Lys Asn Ser Asn
20 25 30
Gin Ile Lys Ile Leu Gly Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gln Lys Glu Glu Val Gln Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gln Gly Gln
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gin Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gln Leu Glu Leu Gln Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gln Asn Gln Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gln Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
47
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Trp Met Glu Trp
210 215 220
Asp Arg Glu Ile Glu Glu Tyr Thr Lys Lys Ile Glu Glu Tyr Thr Lys
225 230 235 240
Lys Ile Glu Glu Tyr Thr Lys Lys Ile Glu Glu Tyr Thr Lys Lys Ile
245 250 255
<210> 50
<211> 236
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-NBP14
<400> 50
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gln Lys Lys Ser Ile Gln Phe His Trp Lys Asn Ser Asn
20 25 30
Gln Ile Lys Ile Leu Gly Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gln Lys Glu Glu Val Gin Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gln Gly Gln
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gln Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gln Leu Glu Leu Gln Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gln Asn Gln Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gln Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Leu Glu Gln
210 215 220
Ile Trp Asn Asn Met Thr Trp Met Gln Trp Asp Lys
225 230 235
<210> 51
<211> 256
<212> PRT
<213> Artificial Sequence
48
<220>
<223> Amino acid sequence of 2D-NBP15
<400> 51
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gin Lys Lys Ser Ile Gin Phe His Trp Lys Asn Ser Asn
20 25 30
Gin Ile Lys Ile Leu Gly Asn Gin Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gin
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gln Lys Glu Glu Val Gin Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gin Gly Gin
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gin Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gin Leu Glu Leu Gin Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gin Asn Gin Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gin Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Giy Ser Tyr Thr Ser Leu
210 215 220
Ile His Ser Leu Ile Glu Glu Ser Gin Asn Gin Gin Glu Lys Asn Glu
225 230 235 240
Gin Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe
245 250 255
<210> 52
<211> 266
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-CBP1
<400> 52
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gin Lys Lys Ser Ile Gin Phe His Trp Lys Asn Ser Asn
20 25 30
Gin Ile Lys Ile Leu Gly Asn Gin Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gin
50 55 60
49
CA 027946322012-10 29
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gin Lys Glu Glu Val Gin Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gin Gly Gin
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gin Cys Arg Ser Pro Arg Gly Lys Asn Ile Gin Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gin Leu Glu Leu Gin Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gin Asn Gin Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gin Lys Ala Ser Ser Ile Gly Giy Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Thr Leu Thr Val
210 215 220
Gin Ala Arg Gin Leu Leu Ser Gly Ile Val Gin Gin Gin Asn Asn Leu
225 230 235 240
Leu Arg Ala Ile Glu Ala Gin Gin His Leu Leu Gin Leu Thr Val Trp
245 250 255
Gly Ile Lys Gin Leu Gin Ala Arg Ile Leu
260 265
<210> 53
<211> 256
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-CBP2
<400> 53
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gin Lys Lys Ser Ile Gin Phe His Trp Lys Asn Ser Asn
20 25 30
Gin Ile Lys Ile Leu Gly Asn Gin Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gin
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Tie Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Giu Val Glu Asp Gin Lys Glu Glu Val Gin Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gin Gly Gin
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gin Cys Arg Ser Pro Arg Gly Lys Asn Ile Gin Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gin Leu Glu Leu Gin Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gin Asn Gin Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gin Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Gly Ile Val
210 215 220
Gin Gin Gin Asn Asn Leu Leu Arg Ala Ile Glu Ala Gin Gin His Leu
225 230 235 240
Leu Gin Leu Thr Val Trp Gly Ile Lys Gin Leu Gin Ala Arg Ile Leu
245 250 255
<210> 54
<211> 254
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-CBP3
<400> 54
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gin Lys Lys Ser Ile Gin Phe His Trp Lys Asn Ser Asn
20 25 30
Gin Ile Lys Ile Leu Gly Asn Gin Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gin
50 55 60
Giy Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gin Lys Glu Glu Val Gin Leu Leu
85 90 95
Val Phe Giy Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gin Gly Gin
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gin Cys Arg Ser Pro Arg Gly Lys Asn Ile Gin Gly Giy Lys Thr Leu
130 135 140
Ser Val Ser Gin Leu Glu Leu Gin Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gin Asn Gin Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gin Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Giy Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Gly Ile Val
210 215 220
Gin Gin Gin Asn Asn Leu Leu Arg Ala Ile Glu Ala Gin Gin His Leu
225 230 235 240
Leu Gin Leu Thr Val Trp Gly Ile Lys Gin Leu Gin Ala Arg
245 250
51
CA 02794632 2012-10 29
<210> 55
<211> 271
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-CBP4
<400> 55
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gln Lys Lys Ser Ile Gln Phe His Trp Lys Asn Ser Asn
20 25 30
Gln Ile Lys Ile Leu Gly Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gln Lys Glu Glu Val Gln Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gln Gly Gln
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gln Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gln Leu Glu Leu Gln Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gln Asn Gln Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gln Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ala Arg Gln
210 215 220
Leu Leu Ser Gly Ile Val Gln Gln Gln Asn Asn Leu Leu Arg Ala Ile
225 230 235 240
Glu Ala Gln Gln His Leu Leu Gln Leu Thr Val Trp Gly Ile Lys Gln
245 250 255
Leu Gln Ala Arg Ile Leu Ala Val Glu Arg Tyr Leu Lys Gin Gln
260 265 270
<210> 56
<211> 258
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-CBPS
<400> 56
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
52
CA 027946322012-10 29
Thr Ala Ser Gin Lys Lys Ser Ile Gin Phe His Trp Lys Asn Ser Asn
20 25 30
Gin Ile Lys Ile Leu Gly Asn Gin Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gin
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gin Lys Glu Glu Val Gin Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gin Gly Gin
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gin Cys Arg Ser Pro Arg Gly Lys Asn Ile Gin Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gin Leu Giu Leu Gin Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gin Asn Gin Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gin Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asn Asn Leu Leu
210 215 220
Arg Ala Ile Glu Ala Gin Gin His Leu Leu Gin Leu Thr Val Trp Gly
225 230 235 240
Ile Lys Gin Leu Gin Ala Arg Ile Leu Ala Val Glu Arg Tyr Leu Lys
245 250 255
Asp Gin
<210> 57
<211> 237
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-CBP6
<400> 57
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gin Lys Lys Ser Ile Gin Phe His Trp Lys Asn Ser Asn
20 25 30
Gin Ile Lys Ile Leu Gly Asn Gin Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gin
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gin Lys Glu Glu Val Gin Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gin Gly Gin
100 105 110
53
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gln Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gln Leu Glu Leu Gln Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gln Asn Gln Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gln Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Leu Leu Gln Leu
210 215 220
Thr Val Trp Gly Ile Lys Gln Leu Gln Ala Arg Ile Leu
225 230 235
<210> 58
<211> 248
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-CBP7
<400> 58
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gln Lys Lys Ser Ile Gin Phe His Trp Lys Asn Ser Asn
20 25 30
Gln Ile Lys Ile Leu Gly Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gln Lys Glu Glu Val Gln Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gln Gly Gln
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gin Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gln Leu Glu Leu Gln Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gln Asn Gln Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gln Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ile Glu Ala Gln
210 215 220
Gln His Leu Leu Gln Leu Thr Val Trp Gly Ile Lys Gln Leu Gln Ala
225 230 235 240
54
CA 027946322012-10 29
Arg Ile Leu Ala Val Glu Arg Tyr
245
<210> 59
<211> 240
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-FBP1
<400> 59
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gln Lys Lys Ser Ile Gln Phe His Trp Lys Asn Ser Asn
20 25 30
Gln Ile Lys Ile Leu Giy Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gin Lys Glu Glu Val Gln Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gln Gly Gln
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gln Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gln Leu Glu Leu Gln Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gln Asn Gln Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gln Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Giy Gly Gly Ser Gly Giy Gly Gly Ser Gly Gly Giy
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Leu Glu Ala Ile
210 215 220
Pro Cys Ser Ile Pro Pro Cys Val Phe Phe Asn Lys Pro Phe Val Phe
225 230 235 240
<210> 60
<211> 240
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-FBP2
<400> 60
Lys Lys Val Val Leu Giy Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
CA 027946322012-10 29
Thr Ala Ser Gin Lys Lys Ser Ile Gin Phe His Trp Lys Asn Ser Asn
20 25 30
Gin Ile Lys Ile Leu Gly Asn Gin Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gin
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gin Lys Glu Glu Val Gin Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gin Gly Gin
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gin Cys Arg Ser Pro Arg Gly Lys Asn Ile Gin Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gin Leu Glu Leu Gin Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gin Asn Gin Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala Phe Gin Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Leu Glu Ala Ile
210 215 220
Pro Cys Ser Ile Pro Pro Cys Val Phe Ala Asn Lys Pro Phe Val Phe
225 230 235 240
<210> 61
<211> 240
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-FBP3
<400> 61
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gin Lys Lys Ser Ile Gin Phe His Trp Lys Asn Ser Asn
20 25 30
Gin Ile Lys Ile Leu Gly Asn Gin Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gin
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gin Lys Glu Glu Val Gin Leu Leu
85 90 95
Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gin Gly Gin
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gin Cys Arg Ser Pro Arg Gly Lys Asn Ile Gin Gly Gly Lys Thr Leu
130 135 140
56
CA 027946322012-10 29
Ser Val Ser Gin Leu Glu Leu Gin Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gin Asn Gin Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala She Gin Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Leu Glu Ala Ile
210 215 220
Pro Cys Ser Ile Pro Pro Cys Phe Leu Phe Asn Lys Pro Phe Val Phe
225 230 235 240
<210> 62
<211> 240
<212> PRT
<213> Artificial Sequence
<220>
<223> Amino acid sequence of 2D-FBP4
<400> 62
Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr Val Glu Leu Thr Cys
1 5 10 15
Thr Ala Ser Gin Lys Lys Ser Ile Gin Phe His Trp Lys Asn Ser Asn
20 25 30
Gin Ile Lys Ile Leu Gly Asn Gin Gly Ser Phe Leu Thr Lys Gly Pro
35 40 45
Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gin
50 55 60
Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys Ile Glu Asp Ser Asp
65 70 75 80
Thr Tyr Ile Cys Glu Val Glu Asp Gin Lys Glu Glu Val Gin Leu Leu
85 90 95
Val She Gly Leu Thr Ala Asn Ser Asp Thr His Leu Leu Gin Gly Gin
100 105 110
Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly Ser Ser Pro Ser Val
115 120 125
Gin Cys Arg Ser Pro Arg Gly Lys Asn Ile Gin Gly Gly Lys Thr Leu
130 135 140
Ser Val Ser Gin Leu Glu Leu Gin Asp Ser Gly Thr Trp Thr Cys Thr
145 150 155 160
Val Leu Gin Asn Gin Lys Lys Val Glu Phe Lys Ile Asp Ile Val Val
165 170 175
Leu Ala She Gin Lys Ala Ser Ser Ile Gly Gly Gly Gly Ser Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
195 200 205
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Leu Glu Ala Ile
210 215 220
Pro Cys Ser Ile Pro Pro Glu Phe Leu She Gly Lys Pro She Val She
225 230 235 240
<210> 63
<211> 35
57
<212> PRT
<213> Human immunodeficiency virus
<400> 63
Trp Glu Glu Trp Asp Lys Lys Ile Glu Glu Tyr Thr Lys Lys Ile Glu
1 5 10 15
Glu Leu Ile Lys Lys Ser Glu Glu Gln Gln Lys Lys Asn Glu Glu Glu
20 25 30
Leu Lys Lys
<210> 64
<211> 53
<212> PRT
<213> Human immunodeficiency virus
<400> 64
Phe Trp Asn Trp Leu Ser Ala Trp Lys Asp Leu Glu Leu Leu Glu Gln
1 5 10 15
Glu Asn Lys Glu Gln Gln Asn Gin Ser Glu Glu Ile Leu Ser His Ile
20 25 30
Leu Ser Thr Tyr Asn Asn Ile Glu Arg Asp Trp Glu Met Trp Thr Met
35 40 45
Asn Asn Trp Ile Gln
58
